Mouse Models of Rheumatoid Arthritis for Studies on Immunopathogenesis and Preclinical Testing of Fc Receptor-Targeting Biologics
Pharmacology · 2020 · 105 (11-12) · 618-629
DOI: 10.1159/000508239 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacology, online erschienen am 22.06.2020. Verfasst von Bonnie J B Lewis und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes inflammation, swelling, and pain in the joints and involves systemic complications. Mouse models of RA have been extensively used to model the pathogenesis of RA and to develop effective therapies. Although many components of the immune system have been studied in these models, the role of crystallizable fragment (Fc) gamma receptors (FcγRs) in RA has been sorely neglected. The aim of this review was to introduce the different mouse models of RA and to describe the different drug development strategies that have been tested in these models to target FcγR function, with the focus being on drugs that have been made from the Fc of immunoglobulin G (IgG). Summary: Evidence suggests that FcγRs play a major role in immune complex-induced inflammation in autoimmune diseases, such as RA. However, there is limited knowledge on the importance of FcγRs in the human disease even though there has been extensive work in mouse models of RA. Numerous mouse models of RA are available, with each model depicting certain aspects of the disease. Induced models of RA have nonspecific immune activation with cartilage-directed autoimmunity, whereas spontaneous models of RA develop without immunization, which results in a more chronic form of arthritis. These models have been used to test FcγR-targeting monoclonal antibodies, intravenous immunoglobulin (IVIg), subcutaneously administered IVIg, and recombinant Fcs for their ability to interact with and modify FcγR function. Recombinant Fcs avidly bind FcγRs and exhibit enhanced therapeutic efficacy in mouse models of RA. Key Message: The therapeutic utility of targeting FcγRs with recombinant Fcs is great and should be explored in human clinical trials for autoimmune diseases, such as RA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
- Centre for Innovation, Canadian Blood Services, Toronto, Ontario, Canada.
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada, don.branch@utoronto.ca.
- Centre for Innovation, Canadian Blood Services, Toronto, Ontario, Canada, don.branch@utoronto.ca.
- Department of Medicine, University of Toronto, Toronto, Ontario, Canada, don.branch@utoronto.ca.
Zitieren
APA
Lewis, B. J. B., & Branch, D. R. (2020). Mouse Models of Rheumatoid Arthritis for Studies on Immunopathogenesis and Preclinical Testing of Fc Receptor-Targeting Biologics. Pharmacology, 105(11-12), 618-629. https://doi.org/10.1159/000508239
Vancouver
Lewis BJB, Branch DR. Mouse Models of Rheumatoid Arthritis for Studies on Immunopathogenesis and Preclinical Testing of Fc Receptor-Targeting Biologics. Pharmacology. 2020;105(11-12):618-629. doi:10.1159/000508239
BibTeX
@article{Lewis2020,
author = {Lewis, Bonnie J B and Branch, Donald R},
title = {Mouse Models of Rheumatoid Arthritis for Studies on Immunopathogenesis and Preclinical Testing of Fc Receptor-Targeting Biologics},
journal = {Pharmacology},
year = {2020},
volume = {105},
number = {11-12},
pages = {618--629},
doi = {10.1159/000508239}
}
EUVIMED